Hosted on MSN14h
Novo Nordisk takes a hit as CagriSema underperforms in weight loss
The Danish company has announced positive results from its Phase III trial of CagriSema but fell short of a previously ...
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.
Novo Nordisk: Why The Market Sell-Off On CagriSema Data May Be Justified
Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...
BioPharma Dive23h
Novo’s next-gen obesity drug misses expectations in closely watched trial
Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the ...
EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss
Novo Nordisk's stock plunges 20% after underwhelming weight-loss trial results for its obesity drug. Analysts say market ...
BioSpace23h
Novo Nosedives on Underwhelming CagriSema Phase III Weight-Loss Data
Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...
Novo Nordisk stock just tanked 25%: here’s what happened
Novo Nordisk posts disappointing update related to its new weight loss drug CagriSema. Novo Nordisk stock is now down 25% ...
BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints
Evan David Seigerman, BMO managing director, joins 'Fast Money' to discuss Novo sinking on its obesity drug data.